AN OPEN LABEL DOSE RANGING, EFFICACY, SAFETY AND TOLERABILITY PHASE IIA STUDY OF TOPICAL RECOMBINANT LYSOSTAPHIN GEL FORMULATION IN SUBJECTS WITH UNCOMPLICATED STAPHYLOCOCCUS AUREUS SKIN AND SKIN STRUCTURE INFECTIONS.

Trial Profile

AN OPEN LABEL DOSE RANGING, EFFICACY, SAFETY AND TOLERABILITY PHASE IIA STUDY OF TOPICAL RECOMBINANT LYSOSTAPHIN GEL FORMULATION IN SUBJECTS WITH UNCOMPLICATED STAPHYLOCOCCUS AUREUS SKIN AND SKIN STRUCTURE INFECTIONS.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Lysostaphin (Primary)
  • Indications Staphylococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top